Interaction Between Ethanol and Diazepam in Mice: Chronobiological Aspects

Total Page:16

File Type:pdf, Size:1020Kb

Interaction Between Ethanol and Diazepam in Mice: Chronobiological Aspects ORIGINAL ARTICLES Department of Pharmacodynamics, Medical University Ło´dz´, Poland Interaction between ethanol and diazepam in mice: chronobiological aspects B. Pietrzak, E. Czarnecka Received July 19, 2004, accepted November 25, 2004 Dr. Boguslawa Pietrzak, Department of Pharmacodynamics, Medical University, Muszyn´skiego 1, 90-151 Ło´dz´, Poland [email protected] Pharmazie 60: 761–764 (2005) The mechanism of action of benzodiazepines and ethanol demonstrates that these agents can syner- gistically affect the central nervous system (CNS). The effects of both ethanol and diazepam are likely to depend on the time of the day when they were administered. Diazepam influence on ethanol-induced sleeping and hypothermic activity in mice as well as the influence of combined administration of these agents on spontaneous locomotor activity and coordination in mice (rota-rod) were investigated. Ex- periments were carried out in the light phase (10:00–12:00 h) and the dark phase (22:00–24:00 h). It was shown that ethanol-induced sleeping time was longer in the dark phase than the light phase, and that ethanol increased spontaneous locomotor activity both in the light and the dark. Ethanol-induced hypothermia was lower in the dark than in the light. Diazepam decreased locomotor activity more strongly in the dark phase than by day. It impaired the hypothermic action of ethanol in the light phase, but did not have such an effect in the dark phase. Diazepam prolonged ethanol-induced sleep in the light phase, enhanced its action on locomotor coordination and decreased the stimulating effect of ethanol on spontaneous locomotor activity in mice. The chronobiological effect of the interaction between diazepam and ethanol seems to be of practical importance (sleep and motor coordination). 1. Introduction study was to observe interactions between ethanol and dia- zepam during the day/night cycle (light and dark phase). One of the new pharmacology specialities is chronophar- macology. It deals with examination of the relationship 2. Investigations and results between timing of drug administration and drug efficacy. Basic concepts of chronopharmacology involve chron- 2.1. Ethanol sleeping time esthesy (circadian changeability of receptor sensitivity to Ethanol administered to mice in a dose of 4 g kgÀ1 pro- drugs) and chronokinetics (circadian rhythms of drug duced sleep lasting about 12 min in a light phase. In a availability, biotransformation and excretion processes). dark phase sleep was longer and lasted on average 21 min. Circadian variations in drug efficacy (chronergy) are the Diazepam prolonged ethanol-induced sleep in the light consequence of chronesthesy and chronokinetics. phase only (Fig. 1). Ethanol has a broad range of actions on many neurotrans- mitter systems. The depressant actions of ethanol in the brain are related in part to facilitation of gamma-aminobu- 35 tiric acid (GABA) neurotransmission via its interaction Light Dark with the benzodiazepine/GABA receptor complex. 30 The benzodiazepines are a family of anxiolytic and hypno- a 25 tic drugs. When taken concurrently with ethanol, a phar- macodynamic interaction may occur, potentiating the cen- 20 tral nervous system depression produced by either drug. c Diazepam is a popular and frequently used benzodiazepine, 15 also indicated in the alcohol abstinence syndrome. The Sleep time [min] 10 GABA-ergic mechanism associated with the action of both benzodiazepines and ethanol can lead to their synergistic ac- 5 tion. The synergistic effect of benzodiazepines and ethanol 0 has been shown in experimental (Van-Steveninck et al. 1996; Et Et+Dz Et Et+Dz Vanover et al. 1999; Vanover 1999; Storustovu and Ebert 2003; Voss et al. 2003) and clinical research (Eves and Lader Fig. 1: The effect of treatment with diazepam on ethanol sleeping time in À1 1989; Hrbek et al. 1989; Van-Steveninck et al. 1996). mice. Et –– ethanol, Dz –– diazepam 0.5 mg kg . Ethanol was given at a dose of 4 g kgÀ1 i.p. ten minutes after diazepam. The Chronobiological aspects of ethanol and diazepam action data are shown as means Æ SEM; a p < 0.05 versus ethanol group, may have essential practical importance. The aim of the cp< 0.05 light versus dark Pharmazie 60 (2005) 10 761 ORIGINAL ARTICLES 4 Light Dark 3 b 2 Time [min] b,c 1 b,d a,b,d 0 Et Et+Dz Dz Sal Et Et+DzDz Sal Fig. 2: The effect of treatment with diazepam on ethanol impairs motor Fig. 4: The effect of treatment with diazepam on ethanol-induced hy- coordination (rota-rod) in mice. Mean time of mice performance on pothermia in mice. Et –– ethanol (2.5 g Á kgÀ1), Dz –– diazepam the rod after treatment with: Et – ethanol (1.5 g Á kgÀ1), Dz –– dia- 0.5 mg kgÀ1, Sal –– saline (0.9% NaCl). Results are presented as zepam 0.5 mg kgÀ1, Sal –– saline (0.9% NaCl). The data are shown means, a p < 0.05 versus ethanol group, b p < 0.05 versus saline as means Æ SEM, a p < 0.05 versus ethanol group, b p < 0.05 group, c p < 0.05 light versus dark versus saline group, c p < 0.05 light versus dark, d p < 0.05 versus diazepam group (Fig. 4). In the dark, hypothermia 90 and 120 min after 2.2. Rota-rod performance ethanol administration was statistically significantly lower than in the light phase. Diazepam given before ethanol in Ethanol impairs motor coordination in mice both in the light the light phase decreased the hypothermic action of etha- and the dark phase, however, it acted more obviously in the nol, whereas it did not exert such an influence in the dark light phase. Diazepam administered in the dark phase before phase (Fig. 4). ethanol resulted in stronger impairment of motor coordina- Diazepam alone decreased mouse body temperature in the tion than was observed after ethanol given alone (Fig. 2). range from 1.4 C to 0.4 C in a similar way in both light and dark phases. 2.3. Spontaneous locomotor activity Ethanol injected at a dose of 2 g Á kgÀ1 increased sponta- 3. Discussion neous locomotor activity in mice both in the light and the The present study has shown that some actions of ethanol dark phase. Diazepam alone clearly decreased mouse are associated with circadian rhythms. The sleeping action spontaneous locomotor activity in the dark. Diazepam ad- has been found to be stronger in the dark than in the light ministered before ethanol significantly decreased mouse phase, however, during the light phase ethanol impairs lo- spontaneous locomotor activity. This activity was apparent comotor coordination to a greater extent and its hypother- in both the light and dark phases (Fig. 3). mic action is more evident. Ethanol affects different neurotransmitters, specific ion 2.4. Ethanol induced hypothermia channel and receptors. It enhances GABA-ergic inhibition increasing the action of g-aminobutyric acid (GABA) on Ethanol administered at a dose of 2.5 g kgÀ1 produced a Á GABA-A receptors (similarly to benzodiazepines) (Korpi marked decrease in mouse body temperature. Mean hy- 1994). This mechanism of action leads to intensification pothermia at 30 min following administration was 4.3 C of the CNS depression produced by ethanol and by benzo- and at 120 min 3 C below the baseline value in the light diazepines. Benzodiazepines give a marked enhancement phase, and in the dark phase 3.2 and 1.2 C, respectively of ethanol induced motor impairment and increased etha- nol sleep time in animals (Vanover et al. 1999; Voss et al. 2003). The chronobiological aspect of ethanol action has a dou- 90 Light Dark ble signifance. The first is the influence of single-dose b 75 b ethanol taken at different times of day and night. The sec- ond problem concerns the effect of chronically adminis- 60 tered ethanol on biological rhythms. c c Investigations on the chronobiological effect of ethanol ac- 45 b tion have been mostly performed in animals and more rarely in humans. Reinberg (1992) defined circadian motility time [%] 30 b changes in the psychological results of ethanol action. a,b,d They were the greatest at 23:00 h and the least at 11:00 h, 15 a,b,d a,b,d a,b,d however, blood pressure values were not associated with 30 min 0 day and night rhythms. Yap et al. (1993) determined ethan- Et Et+Dz Dz Sal Et Et+Dz Dz Sal 60 min ol concentration in blood and air breathed out by 10 healthy volunteers. Ethanol reached its highest blood con- Fig. 3: The influence of diazepam and ethanol on motility in mice. Et – centration at 9:00 h. À1 À1 ethanol (2.0 g kg ), Dz –– diazepam 0.5 mg kg , Sal –– saline Experiments on rats revealed that the pharmacokinetics of (0.9% NaCl). Results are presented as means Æ SEM, a p < 0.05 versus ethanol group, b p < 0.05 versus saline group, c p < 0.05 low but not high ethanol doses are associated with the light versus dark, d p < 0.05 versus diazepam group circadian rhythm. Maximum elimination was observed in 762 Pharmazie 60 (2005) 10 ORIGINAL ARTICLES the dark, i.e. the rats’ active phase (Piekoszewski 1997). It 4. Experimental was also stated that the highest activity of alcohol dehy- 4.1. Animals and treatment drogenase and hepatic microsomal enzymes (MEOS) oc- Treatment experiments were carried out on BALBc male mice (28–35 g). curs just at the time of highest activity of animals (Sturte- The mice were housed in group cages under normal laboratory conditions: vant and Garber 1980). Williams et al. (1993) evaluated temperature of 20–21 C, light/dark cycle (light phase 6.00–18.00, dark the development of tolerance to the hypothermic activity phase 18.00–6.00).
Recommended publications
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Pharmacological Properties of GABAA- Receptors Containing Gamma1
    Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 Molecular PharmacologyThis article hasFast not Forward.been copyedited Published and formatted. on The November final version 7, may 2005 differ as from doi:10.1124/mol.105.017236 this version. MOLPHARM/2005/017236 Pharmacological properties of GABAA- receptors containing gamma1- subunits Khom S.1, Baburin I.1, Timin EN, Hohaus A., Sieghart W., Hering S. Downloaded from Department of Pharmacology and Toxicology, University of Vienna Center of Brain Research , Medical University of Vienna, Division of Biochemistry and molpharm.aspetjournals.org Molecular Biology at ASPET Journals on September 27, 2021 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 This article has not been copyedited and formatted. The final version may differ from this version. MOLPHARM/2005/017236 Running Title: GABAA- receptors containing gamma1- subunits Corresponding author: Steffen Hering Department of Pharmacology and Toxicology University of Vienna Althanstrasse 14 Downloaded from A-1090 Vienna Telephone number: +43-1-4277-55301 Fax number: +43-1-4277-9553 molpharm.aspetjournals.org [email protected] Text pages: 29 at ASPET Journals on September 27, 2021 Tables: 2 Figures: 7 References: 26 Abstract: 236 words Introduction:575 words Discussion:1383 words 2 Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 This article has not been copyedited and formatted. The final version may differ from this version. MOLPHARM/2005/017236 Abstract GABAA receptors composed of α1, β2, γ1-subunits are expressed in only a few areas of the brain and thus represent interesting drug targets.
    [Show full text]
  • WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61K 31/5517 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61P 31/22 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/551 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/NL20 14/050781 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 November 2014 (13.1 1.2014) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/903,433 13 November 2013 (13.
    [Show full text]
  • Rat Animal Models for Screening Medications to Treat Alcohol Use Disorders
    ACCEPTED MANUSCRIPT Selectively Bred Rats Page 1 of 75 Rat Animal Models for Screening Medications to Treat Alcohol Use Disorders Richard L. Bell*1, Sheketha R. Hauser1, Tiebing Liang2, Youssef Sari3, Antoinette Maldonado-Devincci4, and Zachary A. Rodd1 1Indiana University School of Medicine, Department of Psychiatry, Indianapolis, IN 46202, USA 2Indiana University School of Medicine, Department of Gastroenterology, Indianapolis, IN 46202, USA 3University of Toledo, Department of Pharmacology, Toledo, OH 43614, USA 4North Carolina A&T University, Department of Psychology, Greensboro, NC 27411, USA *Send correspondence to: Richard L. Bell, Ph.D.; Associate Professor; Department of Psychiatry; Indiana University School of Medicine; Neuroscience Research Building, NB300C; 320 West 15th Street; Indianapolis, IN 46202; e-mail: [email protected] MANUSCRIPT Key Words: alcohol use disorder; alcoholism; genetically predisposed; selectively bred; pharmacotherapy; family history positive; AA; HAD; P; msP; sP; UChB; WHP Chemical compounds studied in this article Ethanol (PubChem CID: 702); Acamprosate (PubChem CID: 71158); Baclofen (PubChem CID: 2284); Ceftriaxone (PubChem CID: 5479530); Fluoxetine (PubChem CID: 3386); Naltrexone (PubChem CID: 5360515); Prazosin (PubChem CID: 4893); Rolipram (PubChem CID: 5092); Topiramate (PubChem CID: 5284627); Varenicline (PubChem CID: 5310966) ACCEPTED _________________________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Bell, R. L., Hauser, S. R., Liang, T., Sari, Y., Maldonado-Devincci, A., & Rodd, Z. A. (2017). Rat animal models for screening medications to treat alcohol use disorders. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.02.004 ACCEPTED MANUSCRIPT Selectively Bred Rats Page 2 of 75 The purpose of this review is to present animal research models that can be used to screen and/or repurpose medications for the treatment of alcohol abuse and dependence.
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • Effects of Alprazolam on a Model of Human Absences - Rhythmic Metrazol Activity in Rats
    Physiol. Res. 40:361-364, 1991 ______________________ RAPID COMMUNICATION Effects of Alprazolam on a Model of Human Absences - Rhythmic Metrazol Activity in Rats H. KUBOVÂ1’2, P. MARES 1-3 1 Institute o f Physiology, Academy o f Sciences o f the Czech Republic, Departments o f 2 Pharmacology and 3 Pathophysiology,3rd Medical Faculty, Charles University, Prague Received April 6, 1993 Accepted June 10, 1993 Summary Two doses of alprazolam (0.1 and 0.5 mg.kg“ 1) were tested against a model of human absences - rhythmic EEG activity elicited by low doses of pentylenetetrazol (35 mg.kg-1 ) — in 10 unrestrained rats with implanted cortical electrodes. Alprazolam delayed the onset of epileptic EEG activity, decreased the number of rhythmic episodes and shortened the total duration of rhythmic activity in a dose-dependent manner. The average duration of episodes of rhythmic activity remained unchanged; other benzodiazepines studied previously were able to influence this measure. Key words Epileptic seizures - EEG - Pentylenetetrazol - Alprazolam - Rat Benzodiazepines are used in the treatment of Because of this intermediate position we decided to various types of human epilepsies-absences, atypical test this benzodiazepine against rhythmic metrazol absences, Lennox-Gastaut syndrome and myoclonic activity as the first step in delineation of its epilepsies (Burdette and Browne 1990). They are also anticonvulsant activity. efficient against many models of epileptic seizures in Experiments were performed in 10 male experimental animals (for review Schmidt 1989, Sato albino rats of the Wistar strain. Body weight of the 1989), including models of human absences animals at the beginning of experiments ranged from (Marescaux et al.
    [Show full text]
  • Comparative Cue Generalisation Profiles of L-838,417, SL651498
    JPET Fast Forward. Published on December 8, 2005 as DOI: 10.1124/jpet.105.094003 JPET FastThis Forward.article has not Published been copyedited on and December formatted. The 8, final 2005 version as DOI:10.1124/jpet.105.094003may differ from this version. JPET #94003 Title Page Comparative cue generalisation profiles of L-838,417, SL651498, zolpidem, CL218,872, ocinaplon, bretazenil, zopiclone and various benzodiazepines in chlordiazepoxide and zolpidem drug Downloaded from discrimination jpet.aspetjournals.org Mirza NR, Rodgers RJ and Mathiasen LS NeuroSearch A/S, 93 Pederstrupvej, Ballerup, DK-2750, Denmark (NRM, LSM); Behavioural Neuroscience Laboratory, Institute of Psychological at ASPET Journals on October 1, 2021 Sciences, University of Leeds, Leeds LS2 9JT, England (JRR, LSM) 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on December 8, 2005 as DOI: 10.1124/jpet.105.094003 This article has not been copyedited and formatted. The final version may differ from this version. JPET #94003 Running Title Page: Subtype-selective GABAA receptor modulators in drug discrimination Contact and address for correspondence: Naheed R. Mirza Department of In-vivo Pharmacology NeuroSearch A/S 93 Pederstrupvej Downloaded from DK-2750 Ballerup Denmark Tele: +45 44 60 82 71 jpet.aspetjournals.org FAX: +45 44 60 80 80 E-mail: [email protected] at ASPET Journals on October 1, 2021 Number of text pages: 19 Number of tables: 0 Number of figures: 4 Number of references: 35 Number of words in Abstract: 252 Number of words in Introduction: 1028 Number of words in Discussion: 1598 Non-standard abbreviations: None Preferred section assignment: Behavioural Pharmacology 2 JPET Fast Forward.
    [Show full text]
  • Human Pharmacology of Positive GABA-A Subtype-Selective Receptor Modulators for the Treatment of Anxiety
    www.nature.com/aps REVIEW ARTICLE Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety Xia Chen1,2,3,4, Joop van Gerven4,5, Adam Cohen4 and Gabriel Jacobs4 Anxiety disorders arise from disruptions among the highly interconnected circuits that normally serve to process the streams of potentially threatening stimuli. The resulting imbalance among these circuits can cause a fundamental misinterpretation of neural sensory information as threatening and can lead to the inappropriate emotional and behavioral responses observed in anxiety disorders. There is considerable preclinical evidence that the GABAergic system, in general, and its α2- and/or α5-subunit- containing GABA(A) receptor subtypes, in particular, are involved in the pathophysiology of anxiety disorders. However, the clinical efficacy of GABA-A α2-selective agonists for the treatment of anxiety disorders has not been unequivocally demonstrated. In this review, we present several human pharmacological studies that have been performed with the aim of identifying the pharmacologically active doses/exposure levels of several GABA-A subtype-selective novel compounds with potential anxiolytic effects. The pharmacological selectivity of novel α2-subtype-selective GABA(A) receptor partial agonists has been demonstrated by their distinct effect profiles on the neurophysiological and neuropsychological measurements that reflect the functions of multiple CNS domains compared with those of benzodiazepines, which are nonselective, full GABA(A) agonists. Normalizing the undesired pharmacodynamic side effects against the desired on-target effects on the saccadic peak velocity is a useful approach for presenting the pharmacological features of GABA(A)-ergic modulators. Moreover, combining the anxiogenic symptom provocation paradigm with validated neurophysiological and neuropsychological biomarkers may provide further construct validity for the clinical effects of novel anxiolytic agents.
    [Show full text]
  • Pharmacokinetic and Pharmacodynamic Interactions of Bretazenil and Diazepam with Alcohol
    Br J Clin Pharmacol 1996; 41: 565–573 Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol A. L. VAN STEVENINCK1, R. GIESCHKE2, R. C. SCHOEMAKER1, G. RONCARI2, B. TUK1, M. S. M. PIETERS1, D. D. BREIMER3 & A. F. COHEN1 1Centre for Human Drug Research, University Hospital Leiden, The Netherlands, 2Hoffmann-La Roche, Basle, Switzerland and 3Centre for Bio-Pharmaceutical Sciences, Leiden, The Netherlands 1 Interaction between alcohol and bretazenil (a benzodiazepine partial agonist in animals) was studied with diazepam as a comparator in a randomized, double-blind, placebo controlled six-way cross over experiment in 12 healthy volunteers, aged 19−26 years. 2 Bretazenil (0.5 mg), diazepam (10 mg) and matching placebos were given as single oral doses after intravenous infusion of alcohol to a steady target-blood concentration of 0.5 g l−1 or a control infusion of 5% w/v glucose at 1 week intervals. 3 CNS effects were evaluated between 0 and 3.5 h after drug administration by smooth pursuit and saccadic eye movements, adaptive tracking, body sway, digit symbol substitution test and visual analogue scales. 4 Compared with placebo all treatments caused significant decrements in performance. Overall, the following sequence was found for the magnitude of treatment effects: bretazenil+alcohol>diazepam+alcohol≥bretazenil> diazepam>alcohol>placebo. 5 There were no consistent indications for synergistic, supra-additive pharmaco- dynamic interactions between alcohol and bretazenil or diazepam. 6 Bretazenil with or without alcohol, and diazepam+alcohol had marked effects. Because subjects were often too sedated to perform the adaptive tracking test and the eye movement tests adequately, ceiling effects may have affected the outcome of these tests.
    [Show full text]
  • GABAA Receptor a Subunits Differentially Contribute to Diazepam Tolerance After Chronic Treatment
    GABAA Receptor a Subunits Differentially Contribute to Diazepam Tolerance after Chronic Treatment Christiaan H. Vinkers1,2*, Ruud van Oorschot1, Elsebet Ø. Nielsen3, James M. Cook4, Henrik H. Hansen3,5, Lucianne Groenink1, Berend Olivier1,6, Naheed R. Mirza3,7 1 Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands, 2 Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands, 3 NeuroSearch A/S, NsDiscovery, Ballerup, Denmark, 4 Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, United States of America, 5 Gubra ApS, Hørsholm, Denmark, 6 Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America, 7 Aniona ApS, Ballerup, Denmark Abstract Background: Within the GABAA-receptor field, two important questions are what molecular mechanisms underlie benzodiazepine tolerance, and whether tolerance can be ascribed to certain GABAA-receptor subtypes. Methods: We investigated tolerance to acute anxiolytic, hypothermic and sedative effects of diazepam in mice exposed for 28-days to non-selective/selective GABAA-receptor positive allosteric modulators: diazepam (non-selective), bretazenil 3 (partial non-selective), zolpidem (a1 selective) and TPA023 (a2/3 selective). In-vivo binding studies with [ H]flumazenil confirmed compounds occupied CNS GABAA receptors. Results: Chronic diazepam treatment resulted in tolerance to diazepam’s acute anxiolytic, hypothermic and sedative effects. In mice treated chronically with bretazenil, tolerance to diazepam’s anxiolytic and hypothermic, but not sedative, effects was seen. Chronic zolpidem treatment resulted in tolerance to diazepam’s hypothermic effect, but partial anxiolytic tolerance and no sedative tolerance. Chronic TPA023 treatment did not result in tolerance to diazepam’s hypothermic, anxiolytic or sedative effects.
    [Show full text]
  • Data Sharing to Accelerate Therapeutic Development for Rare
    Safe Use of Benzodiazepines: Clinical, Regulatory, and Public Health Perspectives July 12 & 13, 2021 1 Welcome & Overview | Day 1 Mark McClellan Duke-Margolis Center for Health Policy 2 Meeting Agenda Day One Day Two • Session 1: Benzodiazepine Abuse • Session 3: Health Professional Liability, Epidemiology, and and Patient Advocate Clinical Considerations Perspectives – Best Practices, Experiences, and Concerns • Session 2: Clinical, Pharmacologic, and Public • Session 4: Balancing the Benefits Health Perspectives and Risks of Benzodiazepines 3 Virtual Meeting Reminders • Visit the Duke-Margolis website (https://healthpolicy.duke.edu/events) for meeting materials, including the agenda, speaker biographies, and discussion topics. • Questions for our panelists? Feel free to submit questions via Zoom’s Q&A function. • Join the conversation @Duke-Margolis #SafeUseBenzodiazepines #SafeUseBenzodiazepines 4 Opening Remarks from FDA Douglas Throckmorton U.S. Food and Drug Administration 5 Session 1: Benzodiazepine Abuse Liability, Epidemiology, and Clinical Considerations Moderator: Mark McClellan, Duke-Margolis Center for Health Policy 6 Chad Reissig U.S. Food and Drug Administration 7 Pharmacology and Abuse Liability Considerations of Benzodiazepines Chad J. Reissig, PhD, Controlled Substance Staff (CSS) Overview • Brief review of benzodiazepines • Pharmacology of benzodiazepines – Mechanism of action and receptor binding profile – Nonclinical, in vivo, abuse liability data – Clinical pharmacology – Clinical abuse liability data – Dependence/withdrawal-related
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]